Alcami
Trending Articles
Related Content
Regulatory
CorMedix sees NDA approval delay due to CMO and API supplier issue
A Complete Response Letter (CRL) was received from the FDA stating that the DefenCath NDA cannot be approved until deficiencies recently conveyed to the contract manufacturing organisation and the supplier of the API heparin during inspections are resolved